SHShota Harai

Shota Harai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shota Harai has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Nobuyuki Enomoto

    First Department of Internal Medicine Faculty of Medicine, Graduate School of Medicine University of Yamanashi Yamanashi Japan

    2 shared publications
  • Akihiro Ohba

    Department of Hepatobiliary and Pancreatic Oncology National Cancer Center Japan Chuo‐ku Japan

    1 shared publication
  • Ei Takahashi

    First Department of Internal Medicine Faculty of Medicine, Graduate School of Medicine University of Yamanashi Yamanashi Japan

    1 shared publication
  • Hiroko Shindo

    First Department of Internal Medicine Faculty of Medicine, Graduate School of Medicine University of Yamanashi Yamanashi Japan

    1 shared publication
  • Hiromichi Kawaida

    First Department of Surgery; Faculty of Medicine University of Yamanashi Yamanashi Japan

    1 shared publication
  • Hiroshi Hayakawa

    First Department of Internal Medicine Faculty of Medicine, Graduate School of Medicine University of Yamanashi Yamanashi Japan

    1 shared publication

Latest Publications

  • Open Access

    Carcinoembryonic antigen levels in pancreatic juice are associated with histological subtypes of intraductal papillary mucinous neoplasm of the pancreas

    by Hiroshi Hayakawa, Mitsuharu Fukasawa, Shinichi Takano, Hiroko Shindo, Ei Takahashi, Satoshi Kawakami, Yoshimitsu Fukasawa, Natsuhiko Kuratomi, Tadashi Sato, Makoto Kadokura, et al.

    Background: The present study aimed to examine the correlation between preoperative carcinoembryonic antigen levels in pancreatic juice (PJ‐CEA) and the histological subtype of intraductal papillary mucinous neoplasm (IPMN).Methods: We enrolled IPMN patients who underwent endoscopic retrograde pancreatography between March 2002 and March 2018. Clinical factors associated with IPMN histological subtypes of 67 patients who underwent surgery were analyzed. Furthermore, the relationship between CEA immunohistochemistry findings and histological subtypes was investigated.Results: Median PJ‐CEA were 15 ng/ml in the gastric type, 150 ng/ml in the intestinal type, and 175 ng/ml in the pancreatobiliary type. Both intestinal and pancreatobiliary types had significantly higher PJ‐CEA than the gastric type (p = 0.001). In the analysis of histological subtype predictors, high PJ‐CEA (≥63 ng/ml) only showed a significant difference in multivariate analyses (95% confidence interval 4.8–70.2; p < 0.001). Immunohistochemistry findings revealed significantly higher CEA expression in the non‐gastric type than in the gastric type (p < 0.001). The non‐gastric type showed a significantly worse prognosis than the gastric type (p = 0.017).Conclusion: PJ‐CEA was an independent predictor of IPMN histological subtypes in a preoperative setting. High PJ‐CEA predict the non‐gastric type, while low PJ‐CEA predict the gastric type.


  • Usefulness of the laser‐cut, fully covered, self‐expandable metallic stent for endoscopic ultrasound‐guided hepaticogastrostomy

    by Shota Harai, Susumu Hijioka, Yoshikuni Nagashio, Akihiro Ohba, Yuta Maruki, Miyuki Sone, Yutaka Saito, Takuji Okusaka, Mitsuharu Fukasawa, Nobuyuki Enomoto

    Background/Purpose: Endoscopic ultrasound‐guided hepaticogastrostomy (EUS‐HGS) has many associated adverse events. We evaluated the clinical efficacy and safety of the laser‐cut, fully covered, self‐expandable metallic stent (FCSEMS) for this procedure.Methods: This single‐center, retrospective study included cases where EUS‐HGS with a laser‐cut FCSEMS was performed for malignant biliary obstruction. Technical and clinical success, time to recurrent biliary obstruction (TRBO), procedure time, adverse events, and re‐interventions were evaluated.Results: There were 95 eligible cases. Technical and clinical success rates were 100.0% and 95.8%, respectively. Median TRBO was 398 days. RBO causes were hyperplasia (7.4%), debris (3.2%), and migration (4.2%). Adverse events occurred in nine cases (9.5%). Non‐occlusion and focal cholangitis occurred in four cases (4.2%) each. Nineteen patients (20%) underwent combined EUS‐HGS (CH) procedures: antegrade stenting, bridging methods, plastic stent anchoring in SEMS, and EUS‐hepaticoduodenostomy. The solely EUS‐HGS (SH) group had significantly longer median TRBO than the CH group (398 vs 246 days, P = .04). There were no significant differences in adverse events between the two groups. Re‐intervention was performed in 29 cases (technical success rate: 100.0%).Conclusions: Laser‐cut FCSEMS can be safely placed in the bile duct and easily applied during re‐intervention, making it useful in EUS‐HGS.